
This Week in Ophthalmology: Week of October 26, 2024
Key Takeaways
- Dr. John Berdahl discussed clinical trials of travoprost, highlighting its potential impact on ophthalmic treatments.
- Meghan Berkenstock analyzed uveitis incidence and prevalence using the US TriNetX Database, emphasizing associated ocular complications.
This Week in Ophthalmology is a video series highlighting some of the top articles featured on the Ophthalmology Times website.
News from the American Academy of Ophthalmology’s recent annual meeting in Chicago continues to be a hot topic of discussion. This week, we will visit some interesting discussions Sheryl Stevenson and I had with leading KOLs during the conference.
First, let’s take a look at our discussion with Dr. John Berdahl of Vance Thompson Vision, who discusses the clinical trials of travoprost.
Watch: AAO 2024: Clinical trials of travoprost
Next, we discussed Incidence and prevalence of uveitis and associated ocular complications in the US TriNetX Database with Meghan Berkenstockan associate professor of ophthalmology at the Wilmer Eye Institute.
Watch: AAO 2024: Incidence and prevalence of uveitis and associated ocular complications in the US TriNetX Database
We also talked to Dr. Michael Singer, director of clinical research, Medical Center Ophthalmology Associates, shared insights on the results of research on the effectiveness of gel versus traditional drops as anesthesia for intravitreal injections.
Watch: AAO 2024: Chloroprocaine ophthalmic gel as anesthesia for intravitreal injections
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.